Car-t therapy for newly diagnosed myeloma without transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new type of cell therapy, called CAR-T, for people newly diagnosed with myeloma who can't have a stem cell transplant. The therapy uses your own immune cells, changed in a lab to better fight the myeloma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between the ages of 18 and 70.
- You have been newly diagnosed with multiple myeloma (a type of blood cancer).
- You are not able to have a stem cell transplant (a treatment that replaces bone marrow).
- Your liver enzymes (proteins from the liver) are no more than 3 times the normal level.
- You are able to do most daily tasks on your own. Your level of function must be above a certain score.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This study compares two treatments for newly diagnosed multiple myeloma: CAR-T cell therapy and a stem cell transplant. It aims to see which one works better for patients who are eligible for a stem cell transplant.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This study tests a new treatment called CT103A CAR-T therapy for people newly diagnosed with high-risk multiple myeloma. It uses your own immune cells to attack the cancer cells, and may help control the disease even when it's aggressive.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.